216 related articles for article (PubMed ID: 6849356)
1. Relationship of oral contraceptives and the intrauterine contraceptive devices to the regression of concentrations of the beta subunit of human chorionic gonadotropin and invasive complications after molar pregnancy.
Ho Yuen B; Burch P
Am J Obstet Gynecol; 1983 Jan; 145(2):214-7. PubMed ID: 6849356
[TBL] [Abstract][Full Text] [Related]
2. The influence of oral contraceptives on the postmolar human chorionic gonadotropin regression curve.
Morrow P; Nakamura R; Schlaerth J; Gaddis O; Eddy G
Am J Obstet Gynecol; 1985 Apr; 151(7):906-14. PubMed ID: 2580438
[TBL] [Abstract][Full Text] [Related]
3. Identification of choriocarcinoma by the hCG beta-to-hCG proportion in patients with delayed diagnosis caused by contraceptive use.
Vartiainen J; Alfthan H; Lehtovirta P; Stenman UH
Contraception; 1998 Apr; 57(4):257-60. PubMed ID: 9649918
[TBL] [Abstract][Full Text] [Related]
4. Failure of contraceptive steroids to modify human chorionic gonadotrophin secretion by hydatidiform mole tissue and choriocarcinoma cells in culture.
Gal D; Simpson ER; Porter JC; MacDonald PC; Buchsbaum HJ
Steroids; 1981 Jun; 37(6):663-71. PubMed ID: 7027540
[TBL] [Abstract][Full Text] [Related]
5. Oral contraceptives and postmolar trophoblastic disease.
Berkowitz RS; Goldstein DP; Marean AR; Bernstein M
Obstet Gynecol; 1981 Oct; 58(4):474-7. PubMed ID: 6269038
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
[TBL] [Abstract][Full Text] [Related]
7. The secretion of human chorionic gonadotropin-like substance in women employing contraceptive measures.
Huang SC; Chen HC; Chen RJ; Hsieh CY; Wei PY; Ouyang PC
J Clin Endocrinol Metab; 1984 Apr; 58(4):646-53. PubMed ID: 6699130
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy-specific beta 1-glycoprotein and chorionic gonadotropin-like immunoreactivity during the latter half of the cycle in women using intrauterine contraception.
Seppälä M; Rutanen EM; Jalanko H; Lehtovirta P; Stenman UH; Engvall E
J Clin Endocrinol Metab; 1978 Dec; 47(6):1216-9. PubMed ID: 318094
[TBL] [Abstract][Full Text] [Related]
9. Neoplasia of the cervix uteri and contraception: a possible adverse effect of the pill.
Vessey MP; Lawless M; McPherson K; Yeates D
Lancet; 1983 Oct; 2(8356):930-4. PubMed ID: 6138502
[TBL] [Abstract][Full Text] [Related]
10. Absence of chorionic gonadotropin in sera of women who use intrauterine devices.
Segal SJ; Alvarez-Sanchez F; Adejuwon CA; Brache de Mejia V; Leon P; Faundes A
Fertil Steril; 1985 Aug; 44(2):214-8. PubMed ID: 4018277
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
[TBL] [Abstract][Full Text] [Related]
12. Fertility regulation technology: status and prospects.
Segal SJ; Nordberg OS
Popul Bull; 1977 Mar; 31(6):1-25. PubMed ID: 12335682
[TBL] [Abstract][Full Text] [Related]
13. Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review.
Braga A; Maestá I; Short D; Savage P; Harvey R; Seckl MJ
BJOG; 2016 Jul; 123(8):1330-5. PubMed ID: 26444183
[TBL] [Abstract][Full Text] [Related]
14. An analysis of the influences of maternal age, gestational age, contraceptive method, and the mode of primary treatment of patients with hydatidiform moles on the incidence of subsequent chemotherapy.
Stone M; Bagshawe KD
Br J Obstet Gynaecol; 1979 Oct; 86(10):782-92. PubMed ID: 228696
[TBL] [Abstract][Full Text] [Related]
15. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
[TBL] [Abstract][Full Text] [Related]
16. Absence of circulating chorionic gonadotropin in wearers of intrauterine contraceptive devices.
Klein TA; Mishell DR
Am J Obstet Gynecol; 1977 Nov; 129(6):626-8. PubMed ID: 920763
[TBL] [Abstract][Full Text] [Related]
17. Postmolar trophoblastic disease in women using hormonal contraception with and without estrogen.
Eddy GL; Schlaerth JB; Nalick RH; Gaddis O; Nakamura RM; Morrow CP
Obstet Gynecol; 1983 Dec; 62(6):736-40. PubMed ID: 6633999
[TBL] [Abstract][Full Text] [Related]
18. New IPPF statement on breastfeeding, fertility and post-partum contraception.
International Planned Parenthood Federation IPPF. International Medical Advisory Panel IMAP
IPPF Med Bull; 1990 Apr; 24(2):2-4. PubMed ID: 12316285
[TBL] [Abstract][Full Text] [Related]
19. Relationship of oral contraception to development of trophoblastic tumour after evacuation of a hydatidiform mole.
Stone M; Dent J; Kardana A; Bagshawe KD
Br J Obstet Gynaecol; 1976 Dec; 83(12):913-6. PubMed ID: 188441
[TBL] [Abstract][Full Text] [Related]
20. [Historical survey of modern reversible contraceptive methods].
Mbabajende V
Imbonezamuryango; 1986 Apr; (5):14-7. PubMed ID: 12268230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
